



## Cystic Fibrosis and Personalized Medicine

Guest Editors:

**Prof. Dr. Cornelis K. van der Ent**

Department of Pulmonology  
Patient Care, Utrecht University  
Medical Center, Utrecht, The  
Netherlands

**Prof. Dr. Harry G. M. Heijerman**

Department of Pulmonology,  
University Medical Center  
Utrecht, Utrecht, The  
Netherlands

Deadline for manuscript  
submissions:

**closed (25 November 2021)**

### Message from the Guest Editors

Cystic fibrosis is the most prevalent monogenetic disease worldwide. Over 2000 different defects in the cystic fibrosis transmembrane conductance regulator (CFTR) gene have been described, not only leading to a highly diverse phenotype of the disease, but also to the development of a plethora of gene-defect specific therapies. Many new techniques and models have been developed to unravel the genotype-phenotype relationship and to develop and apply new molecules which can modify CFTR-protein function. In addition to clinical and radiological evaluation, functional measurements such as sweat testing, intestinal current measurements, and patient-derived cell models from airway and gut tissue have become available. Today, these tools are more and more helpful in driving treatment of cystic fibrosis into therotyping and real personalized medicine. For this Special Issue, we invite review articles and original studies addressing the latest developments in patient-specific drug development and evaluation of effects in patients with cystic fibrosis.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer  
Institute, Winston-Salem, NC  
27103, USA

2. Division of Hematologic  
Malignancies and Cellular  
Therapy, Duke University,  
Durham, NC 27710, USA

## Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM; ISSN 2075-4426)* is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

**Journal Rank:** JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Journal of Personalized Medicine*  
Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/jpm](http://mdpi.com/journal/jpm)  
[jpm@mdpi.com](mailto:jpm@mdpi.com)  
[X@JPM\\_MDPI](https://twitter.com/JPM_MDPI)